Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBI-05-01
- Development stage
- Unknown
- Lead developer
- Matrix Biomed
- Modality
- Small Molecules
01
Overview
MBI-05-01 (also known as MBM-02) is a Tempol-based small molecule therapeutic developed by Matrix Biomed. It is designed to modulate the activity of Hypoxia-Inducible Factor 1 (HIF-1) and Hypoxia-Inducible Factor 2 (HIF-2), which are master transcription factors that regulate the cellular response to low oxygen levels and are implicated in tumor progression and treatment-related toxicities. MBI-05-01 is specifically being developed to mitigate the toxic side effects associated with doxorubicin and other anthracycline-based chemotherapies, such as cardiotoxicity. The drug is currently in Phase 2 clinical development for these indications.
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)HIF-1 (Hypoxia-inducible factor 1)
Beyond the preview
Go deeper on MBI-05-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBI-05-01.